Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

Muscle Hypertrophy in Healthy Young Men Clinical Trial

Official title:

Role of 11 Weeks of Beta2-adrenergic Signaling and Resistance Training for Cardiac and Skeletal Muscle Hypertrophy in Men

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02551276
• Other study ID #: SAL-STYRKE
• Status: Completed
• Phase: N/A
• First received: September 12, 2015
• Last updated: March 14, 2016
• Start date: November 2013
• Est. completion date: November 2015

Study information

• Verified date: March 2016
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Scientific Ethics Committees of Denmark
• Study type: Interventional

Clinical Trial Summary

Studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. These effects may be mediated by cAMP/PKA dependent activation of several downstream sites that modulate protein synthesis and breakdown. While the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. The purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (cAMP/PKA-signaling) on muscle hypertrophy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: November 2015
• Est. primary completion date: November 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Physical active

• Non-smokers

• Non-asthmatics

• No chronic diseases

• Informed consent

Exclusion Criteria:

• Smoker

• Allergy towards study drug

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Hypertrophy
• Muscle Hypertrophy in Healthy Young Men

Intervention

Drug:
• Salbutamol

• Placebo

Other:
• Resistance training

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Copenhagen	Bispebjerg Hospital, University of Southern Denmark

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skeletal Muscle Hypertrophy (lean body mass in Kilograms)	Lean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)	2 days	No
Secondary	Left Ventricular Hypertrophy (mass in grams)	Left Ventricular Mass (g) will be measured by echocardiography of the heart	1 day	No